Hologen is a secretive AI biotech startup co-founded by former Google CEO Eric Schmidt. The company is seeking to raise $150 million in a Series A funding round to be led by Averin and Atlas. Hologen describes itself as a frontier medical AI company focused on drug development, diagnostics and investment. It emerged from University College London and King's College London and received seed funding from the family investment office SW7 and from Schmidt. He plans to build "large-scale medical models" that take into account variability in people's biology and responses to treatment, thereby revealing the true effects of drugs in late-stage trials and reducing the risks of clinical trials. The models will leverage the experience of Chief AI Officer Jorge Cardoso's team with the MONAI platform and data from 8 years of exclusive partnerships with UK NHS health trusts. In March 2025, it formed a joint venture Hologen Neuro AI with MeiraGTx to develop gene therapies against Parkinson's disease and obesity, providing $230 million in funding.[1][2][3][4]